A comparative longitudinal quality of life study using the Spitzer quality of life index in a randomized multicenter phase III trial (FFCD 9102): chemoradiation followed by surgery compared with chemoradiation alone in locally advanced squamous resectable thoracic esophageal cancer
Identifieur interne : 001761 ( Istex/Corpus ); précédent : 001760; suivant : 001762A comparative longitudinal quality of life study using the Spitzer quality of life index in a randomized multicenter phase III trial (FFCD 9102): chemoradiation followed by surgery compared with chemoradiation alone in locally advanced squamous resectable thoracic esophageal cancer
Auteurs : F. Bonnetain ; O. Bouche ; P. Michel ; C. Mariette ; T. Conroy ; D. Pezet ; B. Roullet ; J.-F. Seitz ; B. Paillot ; P. Arveux ; C. Milan ; L. BedenneSource :
- Annals of Oncology [ 0923-7534 ] ; 2006-05.
English descriptors
- KwdEn :
Abstract
Background: The aim of the study was to compare the longitudinal quality of life (QoL) between chemoradiation with or without surgery in patients with locally advanced squamous resectable esophageal cancer included in a randomized multicenter phase III trial (FFCD 9102). Materials and methods: All patients with locally advanced resectable (T3–4 N0–1 M0) epidermoid or glandular esophageal cancer (n = 451) received induction chemoradiation. Responders (n = 259) were randomized between surgery (arm A) and continuation of chemoradiation (arm B). The Spitzer QoL Index was scored (0–10) at inclusion and at each follow-up, every 3 months during 2 years. QoL at baseline and longitudinal changes were respectively compared with univariate ANOVA and mixed-model analysis of variance for repeated measurements. The time interval between the follow-up was assessed and the same analyses were performed among survivors with 2 years of follow-up. Results: The squamous histology was predominant in both arms. The mean QoL score decreased between baseline and the first follow-up and between the first and the second follow-ups. QoL scores at the first follow-up were comparatively worse in arm A than in arm B (7.52 versus 8.45, P < 0.01), whereas the longitudinal QoL study showed no difference between treatments (adjusted P = 0.26). Furthermore, the longitudinal QoL was not different (adjusted P = 0.23) among survivors with 2 years of follow-up. Conclusions: Among patients responding to induction chemoradiation, surgery and continuation of chemoradiation had the same impact on QoL in patients with locally advanced, resectable esophageal cancer although a significantly greater decrease in the Spitzer Index was observed in the postoperative period.
Url:
DOI: 10.1093/annonc/mdl033
Links to Exploration step
ISTEX:FDE39442EAAA5F05C7C30FA79230D923131D83A9Le document en format XML
<record><TEI wicri:istexFullTextTei="biblStruct"><teiHeader><fileDesc><titleStmt><title xml:lang="en">A comparative longitudinal quality of life study using the Spitzer quality of life index in a randomized multicenter phase III trial (FFCD 9102): chemoradiation followed by surgery compared with chemoradiation alone in locally advanced squamous resectable thoracic esophageal cancer</title><author><name sortKey="Bonnetain, F" sort="Bonnetain, F" uniqKey="Bonnetain F" first="F." last="Bonnetain">F. Bonnetain</name><affiliation><mods:affiliation>Fédération Francophone de Cancérologie Digestive (FFCD) and Equipe Mixte Inserm (EMI 106), Faculté de Médecine Dijon;</mods:affiliation></affiliation></author><author><name sortKey="Bouche, O" sort="Bouche, O" uniqKey="Bouche O" first="O." last="Bouche">O. Bouche</name><affiliation><mods:affiliation>Centre Hospitalier Universitaire Robert Debré, Reims;</mods:affiliation></affiliation><affiliation><mods:affiliation>Fédération Francophone de Cancérologie Digestive (FFCD) and Equipe Mixte Inserm (EMI 106), Faculté de Médecine Dijon;</mods:affiliation></affiliation></author><author><name sortKey="Michel, P" sort="Michel, P" uniqKey="Michel P" first="P." last="Michel">P. Michel</name><affiliation><mods:affiliation>Centre Hospitalier Universitaire Charles Nicolle, Rouen;</mods:affiliation></affiliation><affiliation><mods:affiliation>Fédération Francophone de Cancérologie Digestive (FFCD) and Equipe Mixte Inserm (EMI 106), Faculté de Médecine Dijon;</mods:affiliation></affiliation></author><author><name sortKey="Mariette, C" sort="Mariette, C" uniqKey="Mariette C" first="C." last="Mariette">C. Mariette</name><affiliation><mods:affiliation>Centre Hospitalier Universitaire Claude Huriez, Lille;</mods:affiliation></affiliation><affiliation><mods:affiliation>Fédération Francophone de Cancérologie Digestive (FFCD) and Equipe Mixte Inserm (EMI 106), Faculté de Médecine Dijon;</mods:affiliation></affiliation></author><author><name sortKey="Conroy, T" sort="Conroy, T" uniqKey="Conroy T" first="T." last="Conroy">T. Conroy</name><affiliation><mods:affiliation>Centre Alexis Vautrin, Nancy;</mods:affiliation></affiliation><affiliation><mods:affiliation>Fédération Francophone de Cancérologie Digestive (FFCD) and Equipe Mixte Inserm (EMI 106), Faculté de Médecine Dijon;</mods:affiliation></affiliation></author><author><name sortKey="Pezet, D" sort="Pezet, D" uniqKey="Pezet D" first="D." last="Pezet">D. Pezet</name><affiliation><mods:affiliation>Centre Hospitalier Universitaire Hôtel Dieu, Clermond Ferrand;</mods:affiliation></affiliation><affiliation><mods:affiliation>Fédération Francophone de Cancérologie Digestive (FFCD) and Equipe Mixte Inserm (EMI 106), Faculté de Médecine Dijon;</mods:affiliation></affiliation></author><author><name sortKey="Roullet, B" sort="Roullet, B" uniqKey="Roullet B" first="B." last="Roullet">B. Roullet</name><affiliation><mods:affiliation>Centre Hospitalier Universitaire Dupuytren, Limoges;</mods:affiliation></affiliation><affiliation><mods:affiliation>Fédération Francophone de Cancérologie Digestive (FFCD) and Equipe Mixte Inserm (EMI 106), Faculté de Médecine Dijon;</mods:affiliation></affiliation></author><author><name sortKey="Seitz, J F" sort="Seitz, J F" uniqKey="Seitz J" first="J.-F." last="Seitz">J.-F. Seitz</name><affiliation><mods:affiliation>Institut Paoli-Calmettes, Marseille;</mods:affiliation></affiliation><affiliation><mods:affiliation>Fédération Francophone de Cancérologie Digestive (FFCD) and Equipe Mixte Inserm (EMI 106), Faculté de Médecine Dijon;</mods:affiliation></affiliation></author><author><name sortKey="Paillot, B" sort="Paillot, B" uniqKey="Paillot B" first="B." last="Paillot">B. Paillot</name><affiliation><mods:affiliation>Centre Hospitalier Universitaire du Rouen, Rouen, France</mods:affiliation></affiliation><affiliation><mods:affiliation>Fédération Francophone de Cancérologie Digestive (FFCD) and Equipe Mixte Inserm (EMI 106), Faculté de Médecine Dijon;</mods:affiliation></affiliation></author><author><name sortKey="Arveux, P" sort="Arveux, P" uniqKey="Arveux P" first="P." last="Arveux">P. Arveux</name><affiliation><mods:affiliation>Centre Georges Francois Leclerc, DIM, Dijon;</mods:affiliation></affiliation><affiliation><mods:affiliation>Fédération Francophone de Cancérologie Digestive (FFCD) and Equipe Mixte Inserm (EMI 106), Faculté de Médecine Dijon;</mods:affiliation></affiliation></author><author><name sortKey="Milan, C" sort="Milan, C" uniqKey="Milan C" first="C." last="Milan">C. Milan</name><affiliation><mods:affiliation>Fédération Francophone de Cancérologie Digestive (FFCD) and Equipe Mixte Inserm (EMI 106), Faculté de Médecine Dijon;</mods:affiliation></affiliation><affiliation><mods:affiliation>Fédération Francophone de Cancérologie Digestive (FFCD) and Equipe Mixte Inserm (EMI 106), Faculté de Médecine Dijon;</mods:affiliation></affiliation></author><author><name sortKey="Bedenne, L" sort="Bedenne, L" uniqKey="Bedenne L" first="L." last="Bedenne">L. Bedenne</name><affiliation><mods:affiliation>Fédération Francophone de Cancérologie Digestive (FFCD) and Equipe Mixte Inserm (EMI 106), Faculté de Médecine Dijon;</mods:affiliation></affiliation><affiliation><mods:affiliation>Fédération Francophone de Cancérologie Digestive (FFCD) and Equipe Mixte Inserm (EMI 106), Faculté de Médecine Dijon;</mods:affiliation></affiliation></author></titleStmt><publicationStmt><idno type="wicri:source">ISTEX</idno><idno type="RBID">ISTEX:FDE39442EAAA5F05C7C30FA79230D923131D83A9</idno><date when="2006" year="2006">2006</date><idno type="doi">10.1093/annonc/mdl033</idno><idno type="url">https://api.istex.fr/document/FDE39442EAAA5F05C7C30FA79230D923131D83A9/fulltext/pdf</idno><idno type="wicri:Area/Istex/Corpus">001761</idno></publicationStmt><sourceDesc><biblStruct><analytic><title level="a" type="main" xml:lang="en">A comparative longitudinal quality of life study using the Spitzer quality of life index in a randomized multicenter phase III trial (FFCD 9102): chemoradiation followed by surgery compared with chemoradiation alone in locally advanced squamous resectable thoracic esophageal cancer</title><author><name sortKey="Bonnetain, F" sort="Bonnetain, F" uniqKey="Bonnetain F" first="F." last="Bonnetain">F. Bonnetain</name><affiliation><mods:affiliation>Fédération Francophone de Cancérologie Digestive (FFCD) and Equipe Mixte Inserm (EMI 106), Faculté de Médecine Dijon;</mods:affiliation></affiliation></author><author><name sortKey="Bouche, O" sort="Bouche, O" uniqKey="Bouche O" first="O." last="Bouche">O. Bouche</name><affiliation><mods:affiliation>Centre Hospitalier Universitaire Robert Debré, Reims;</mods:affiliation></affiliation><affiliation><mods:affiliation>Fédération Francophone de Cancérologie Digestive (FFCD) and Equipe Mixte Inserm (EMI 106), Faculté de Médecine Dijon;</mods:affiliation></affiliation></author><author><name sortKey="Michel, P" sort="Michel, P" uniqKey="Michel P" first="P." last="Michel">P. Michel</name><affiliation><mods:affiliation>Centre Hospitalier Universitaire Charles Nicolle, Rouen;</mods:affiliation></affiliation><affiliation><mods:affiliation>Fédération Francophone de Cancérologie Digestive (FFCD) and Equipe Mixte Inserm (EMI 106), Faculté de Médecine Dijon;</mods:affiliation></affiliation></author><author><name sortKey="Mariette, C" sort="Mariette, C" uniqKey="Mariette C" first="C." last="Mariette">C. Mariette</name><affiliation><mods:affiliation>Centre Hospitalier Universitaire Claude Huriez, Lille;</mods:affiliation></affiliation><affiliation><mods:affiliation>Fédération Francophone de Cancérologie Digestive (FFCD) and Equipe Mixte Inserm (EMI 106), Faculté de Médecine Dijon;</mods:affiliation></affiliation></author><author><name sortKey="Conroy, T" sort="Conroy, T" uniqKey="Conroy T" first="T." last="Conroy">T. Conroy</name><affiliation><mods:affiliation>Centre Alexis Vautrin, Nancy;</mods:affiliation></affiliation><affiliation><mods:affiliation>Fédération Francophone de Cancérologie Digestive (FFCD) and Equipe Mixte Inserm (EMI 106), Faculté de Médecine Dijon;</mods:affiliation></affiliation></author><author><name sortKey="Pezet, D" sort="Pezet, D" uniqKey="Pezet D" first="D." last="Pezet">D. Pezet</name><affiliation><mods:affiliation>Centre Hospitalier Universitaire Hôtel Dieu, Clermond Ferrand;</mods:affiliation></affiliation><affiliation><mods:affiliation>Fédération Francophone de Cancérologie Digestive (FFCD) and Equipe Mixte Inserm (EMI 106), Faculté de Médecine Dijon;</mods:affiliation></affiliation></author><author><name sortKey="Roullet, B" sort="Roullet, B" uniqKey="Roullet B" first="B." last="Roullet">B. Roullet</name><affiliation><mods:affiliation>Centre Hospitalier Universitaire Dupuytren, Limoges;</mods:affiliation></affiliation><affiliation><mods:affiliation>Fédération Francophone de Cancérologie Digestive (FFCD) and Equipe Mixte Inserm (EMI 106), Faculté de Médecine Dijon;</mods:affiliation></affiliation></author><author><name sortKey="Seitz, J F" sort="Seitz, J F" uniqKey="Seitz J" first="J.-F." last="Seitz">J.-F. Seitz</name><affiliation><mods:affiliation>Institut Paoli-Calmettes, Marseille;</mods:affiliation></affiliation><affiliation><mods:affiliation>Fédération Francophone de Cancérologie Digestive (FFCD) and Equipe Mixte Inserm (EMI 106), Faculté de Médecine Dijon;</mods:affiliation></affiliation></author><author><name sortKey="Paillot, B" sort="Paillot, B" uniqKey="Paillot B" first="B." last="Paillot">B. Paillot</name><affiliation><mods:affiliation>Centre Hospitalier Universitaire du Rouen, Rouen, France</mods:affiliation></affiliation><affiliation><mods:affiliation>Fédération Francophone de Cancérologie Digestive (FFCD) and Equipe Mixte Inserm (EMI 106), Faculté de Médecine Dijon;</mods:affiliation></affiliation></author><author><name sortKey="Arveux, P" sort="Arveux, P" uniqKey="Arveux P" first="P." last="Arveux">P. Arveux</name><affiliation><mods:affiliation>Centre Georges Francois Leclerc, DIM, Dijon;</mods:affiliation></affiliation><affiliation><mods:affiliation>Fédération Francophone de Cancérologie Digestive (FFCD) and Equipe Mixte Inserm (EMI 106), Faculté de Médecine Dijon;</mods:affiliation></affiliation></author><author><name sortKey="Milan, C" sort="Milan, C" uniqKey="Milan C" first="C." last="Milan">C. Milan</name><affiliation><mods:affiliation>Fédération Francophone de Cancérologie Digestive (FFCD) and Equipe Mixte Inserm (EMI 106), Faculté de Médecine Dijon;</mods:affiliation></affiliation><affiliation><mods:affiliation>Fédération Francophone de Cancérologie Digestive (FFCD) and Equipe Mixte Inserm (EMI 106), Faculté de Médecine Dijon;</mods:affiliation></affiliation></author><author><name sortKey="Bedenne, L" sort="Bedenne, L" uniqKey="Bedenne L" first="L." last="Bedenne">L. Bedenne</name><affiliation><mods:affiliation>Fédération Francophone de Cancérologie Digestive (FFCD) and Equipe Mixte Inserm (EMI 106), Faculté de Médecine Dijon;</mods:affiliation></affiliation><affiliation><mods:affiliation>Fédération Francophone de Cancérologie Digestive (FFCD) and Equipe Mixte Inserm (EMI 106), Faculté de Médecine Dijon;</mods:affiliation></affiliation></author></analytic><monogr></monogr><series><title level="j">Annals of Oncology</title><title level="j" type="abbrev">Ann Oncol</title><idno type="ISSN">0923-7534</idno><idno type="eISSN">1569-8041</idno><imprint><publisher>Oxford University Press</publisher><date type="published" when="2006-05">2006-05</date><biblScope unit="volume">17</biblScope><biblScope unit="issue">5</biblScope><biblScope unit="page" from="827">827</biblScope><biblScope unit="page" to="834">834</biblScope></imprint><idno type="ISSN">0923-7534</idno></series><idno type="istex">FDE39442EAAA5F05C7C30FA79230D923131D83A9</idno><idno type="DOI">10.1093/annonc/mdl033</idno><idno type="local">mdl033</idno></biblStruct></sourceDesc><seriesStmt><idno type="ISSN">0923-7534</idno></seriesStmt></fileDesc><profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>clinical trials</term><term>esophageal cancer</term><term>longitudinal</term><term>quality of life</term><term>radio-chemotherapy</term><term>surgery</term></keywords></textClass><langUsage><language ident="en">en</language></langUsage></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">Background: The aim of the study was to compare the longitudinal quality of life (QoL) between chemoradiation with or without surgery in patients with locally advanced squamous resectable esophageal cancer included in a randomized multicenter phase III trial (FFCD 9102). Materials and methods: All patients with locally advanced resectable (T3–4 N0–1 M0) epidermoid or glandular esophageal cancer (n = 451) received induction chemoradiation. Responders (n = 259) were randomized between surgery (arm A) and continuation of chemoradiation (arm B). The Spitzer QoL Index was scored (0–10) at inclusion and at each follow-up, every 3 months during 2 years. QoL at baseline and longitudinal changes were respectively compared with univariate ANOVA and mixed-model analysis of variance for repeated measurements. The time interval between the follow-up was assessed and the same analyses were performed among survivors with 2 years of follow-up. Results: The squamous histology was predominant in both arms. The mean QoL score decreased between baseline and the first follow-up and between the first and the second follow-ups. QoL scores at the first follow-up were comparatively worse in arm A than in arm B (7.52 versus 8.45, P < 0.01), whereas the longitudinal QoL study showed no difference between treatments (adjusted P = 0.26). Furthermore, the longitudinal QoL was not different (adjusted P = 0.23) among survivors with 2 years of follow-up. Conclusions: Among patients responding to induction chemoradiation, surgery and continuation of chemoradiation had the same impact on QoL in patients with locally advanced, resectable esophageal cancer although a significantly greater decrease in the Spitzer Index was observed in the postoperative period.</div></front></TEI><istex><corpusName>oup</corpusName><author><json:item><name>F. Bonnetain</name><affiliations><json:string>Fédération Francophone de Cancérologie Digestive (FFCD) and Equipe Mixte Inserm (EMI 106), Faculté de Médecine Dijon;</json:string><json:string>E-mail: FBonnetain@dijon.fnclcc.fr</json:string></affiliations></json:item><json:item><name>O. Bouché</name><affiliations><json:string>Centre Hospitalier Universitaire Robert Debré, Reims;</json:string><json:string>Fédération Francophone de Cancérologie Digestive (FFCD) and Equipe Mixte Inserm (EMI 106), Faculté de Médecine Dijon;</json:string></affiliations></json:item><json:item><name>P. Michel</name><affiliations><json:string>Centre Hospitalier Universitaire Charles Nicolle, Rouen;</json:string><json:string>Fédération Francophone de Cancérologie Digestive (FFCD) and Equipe Mixte Inserm (EMI 106), Faculté de Médecine Dijon;</json:string></affiliations></json:item><json:item><name>C. Mariette</name><affiliations><json:string>Centre Hospitalier Universitaire Claude Huriez, Lille;</json:string><json:string>Fédération Francophone de Cancérologie Digestive (FFCD) and Equipe Mixte Inserm (EMI 106), Faculté de Médecine Dijon;</json:string></affiliations></json:item><json:item><name>T. Conroy</name><affiliations><json:string>Centre Alexis Vautrin, Nancy;</json:string><json:string>Fédération Francophone de Cancérologie Digestive (FFCD) and Equipe Mixte Inserm (EMI 106), Faculté de Médecine Dijon;</json:string></affiliations></json:item><json:item><name>D. Pezet</name><affiliations><json:string>Centre Hospitalier Universitaire Hôtel Dieu, Clermond Ferrand;</json:string><json:string>Fédération Francophone de Cancérologie Digestive (FFCD) and Equipe Mixte Inserm (EMI 106), Faculté de Médecine Dijon;</json:string></affiliations></json:item><json:item><name>B. Roullet</name><affiliations><json:string>Centre Hospitalier Universitaire Dupuytren, Limoges;</json:string><json:string>Fédération Francophone de Cancérologie Digestive (FFCD) and Equipe Mixte Inserm (EMI 106), Faculté de Médecine Dijon;</json:string></affiliations></json:item><json:item><name>J.-F. Seitz</name><affiliations><json:string>Institut Paoli-Calmettes, Marseille;</json:string><json:string>Fédération Francophone de Cancérologie Digestive (FFCD) and Equipe Mixte Inserm (EMI 106), Faculté de Médecine Dijon;</json:string></affiliations></json:item><json:item><name>B. Paillot</name><affiliations><json:string>Centre Hospitalier Universitaire du Rouen, Rouen, France</json:string><json:string>Fédération Francophone de Cancérologie Digestive (FFCD) and Equipe Mixte Inserm (EMI 106), Faculté de Médecine Dijon;</json:string></affiliations></json:item><json:item><name>P. Arveux</name><affiliations><json:string>Centre Georges Francois Leclerc, DIM, Dijon;</json:string><json:string>Fédération Francophone de Cancérologie Digestive (FFCD) and Equipe Mixte Inserm (EMI 106), Faculté de Médecine Dijon;</json:string></affiliations></json:item><json:item><name>C. Milan</name><affiliations><json:string>Fédération Francophone de Cancérologie Digestive (FFCD) and Equipe Mixte Inserm (EMI 106), Faculté de Médecine Dijon;</json:string><json:string>Fédération Francophone de Cancérologie Digestive (FFCD) and Equipe Mixte Inserm (EMI 106), Faculté de Médecine Dijon;</json:string></affiliations></json:item><json:item><name>L. Bedenne</name><affiliations><json:string>Fédération Francophone de Cancérologie Digestive (FFCD) and Equipe Mixte Inserm (EMI 106), Faculté de Médecine Dijon;</json:string><json:string>Fédération Francophone de Cancérologie Digestive (FFCD) and Equipe Mixte Inserm (EMI 106), Faculté de Médecine Dijon;</json:string></affiliations></json:item></author><subject><json:item><lang><json:string>eng</json:string></lang><value>quality of life</value></json:item><json:item><lang><json:string>eng</json:string></lang><value>esophageal cancer</value></json:item><json:item><lang><json:string>eng</json:string></lang><value>clinical trials</value></json:item><json:item><lang><json:string>eng</json:string></lang><value>longitudinal</value></json:item><json:item><lang><json:string>eng</json:string></lang><value>surgery</value></json:item><json:item><lang><json:string>eng</json:string></lang><value>radio-chemotherapy</value></json:item></subject><language><json:string>eng</json:string></language><originalGenre><json:string>research-article</json:string></originalGenre><abstract>Background: The aim of the study was to compare the longitudinal quality of life (QoL) between chemoradiation with or without surgery in patients with locally advanced squamous resectable esophageal cancer included in a randomized multicenter phase III trial (FFCD 9102). Materials and methods: All patients with locally advanced resectable (T3–4 N0–1 M0) epidermoid or glandular esophageal cancer (n = 451) received induction chemoradiation. Responders (n = 259) were randomized between surgery (arm A) and continuation of chemoradiation (arm B). The Spitzer QoL Index was scored (0–10) at inclusion and at each follow-up, every 3 months during 2 years. QoL at baseline and longitudinal changes were respectively compared with univariate ANOVA and mixed-model analysis of variance for repeated measurements. The time interval between the follow-up was assessed and the same analyses were performed among survivors with 2 years of follow-up. Results: The squamous histology was predominant in both arms. The mean QoL score decreased between baseline and the first follow-up and between the first and the second follow-ups. QoL scores at the first follow-up were comparatively worse in arm A than in arm B (7.52 versus 8.45, P > 0.01), whereas the longitudinal QoL study showed no difference between treatments (adjusted P = 0.26). Furthermore, the longitudinal QoL was not different (adjusted P = 0.23) among survivors with 2 years of follow-up. Conclusions: Among patients responding to induction chemoradiation, surgery and continuation of chemoradiation had the same impact on QoL in patients with locally advanced, resectable esophageal cancer although a significantly greater decrease in the Spitzer Index was observed in the postoperative period.</abstract><qualityIndicators><score>8</score><pdfVersion>1.3</pdfVersion><pdfPageSize>612 x 791 pts</pdfPageSize><refBibsNative>false</refBibsNative><keywordCount>6</keywordCount><abstractCharCount>1752</abstractCharCount><pdfWordCount>5791</pdfWordCount><pdfCharCount>38752</pdfCharCount><pdfPageCount>8</pdfPageCount><abstractWordCount>262</abstractWordCount></qualityIndicators><title>A comparative longitudinal quality of life study using the Spitzer quality of life index in a randomized multicenter phase III trial (FFCD 9102): chemoradiation followed by surgery compared with chemoradiation alone in locally advanced squamous resectable thoracic esophageal cancer</title><genre><json:string>research-article</json:string></genre><host><volume>17</volume><publisherId><json:string>annonc</json:string></publisherId><pages><last>834</last><first>827</first></pages><issn><json:string>0923-7534</json:string></issn><issue>5</issue><genre><json:string>journal</json:string></genre><language><json:string>unknown</json:string></language><eissn><json:string>1569-8041</json:string></eissn><title>Annals of Oncology</title></host><categories><wos><json:string>ONCOLOGY</json:string></wos></categories><publicationDate>2006</publicationDate><copyrightDate>2006</copyrightDate><doi><json:string>10.1093/annonc/mdl033</json:string></doi><id>FDE39442EAAA5F05C7C30FA79230D923131D83A9</id><score>0.10708964</score><fulltext><json:item><original>true</original><mimetype>application/pdf</mimetype><extension>pdf</extension><uri>https://api.istex.fr/document/FDE39442EAAA5F05C7C30FA79230D923131D83A9/fulltext/pdf</uri></json:item><json:item><original>false</original><mimetype>application/zip</mimetype><extension>zip</extension><uri>https://api.istex.fr/document/FDE39442EAAA5F05C7C30FA79230D923131D83A9/fulltext/zip</uri></json:item><istex:fulltextTEI uri="https://api.istex.fr/document/FDE39442EAAA5F05C7C30FA79230D923131D83A9/fulltext/tei"><teiHeader><fileDesc><titleStmt><title level="a" type="main" xml:lang="en">A comparative longitudinal quality of life study using the Spitzer quality of life index in a randomized multicenter phase III trial (FFCD 9102): chemoradiation followed by surgery compared with chemoradiation alone in locally advanced squamous resectable thoracic esophageal cancer</title><respStmt><resp>Références bibliographiques récupérées via GROBID</resp><name resp="ISTEX-API">ISTEX-API (INIST-CNRS)</name></respStmt></titleStmt><publicationStmt><authority>ISTEX</authority><publisher>Oxford University Press</publisher><availability><p>© 2006 European Society for Medical Oncology</p></availability><date>2006-03-08</date></publicationStmt><notesStmt><note>*Correspondence to: Dr F. Bonnetain, Féderation Francophone de Cancérologie Digestive, Faculty of Medicine, 7 Boulevard Jeanne d'Arc, 21079 Dijon Cedex, France. Tel: +33-3-80-39-33-40; Fax: +33-3-80-66-82-51; E-mail: FBonnetain@dijon.fnclcc.fr</note></notesStmt><sourceDesc><biblStruct type="inbook"><analytic><title level="a" type="main" xml:lang="en">A comparative longitudinal quality of life study using the Spitzer quality of life index in a randomized multicenter phase III trial (FFCD 9102): chemoradiation followed by surgery compared with chemoradiation alone in locally advanced squamous resectable thoracic esophageal cancer</title><author xml:id="author-1"><persName><forename type="first">F.</forename><surname>Bonnetain</surname></persName><affiliation>Fédération Francophone de Cancérologie Digestive (FFCD) and Equipe Mixte Inserm (EMI 106), Faculté de Médecine Dijon;</affiliation></author><author xml:id="author-2"><persName><forename type="first">O.</forename><surname>Bouché</surname></persName><affiliation>Centre Hospitalier Universitaire Robert Debré, Reims;</affiliation><affiliation>Fédération Francophone de Cancérologie Digestive (FFCD) and Equipe Mixte Inserm (EMI 106), Faculté de Médecine Dijon;</affiliation></author><author xml:id="author-3"><persName><forename type="first">P.</forename><surname>Michel</surname></persName><affiliation>Centre Hospitalier Universitaire Charles Nicolle, Rouen;</affiliation><affiliation>Fédération Francophone de Cancérologie Digestive (FFCD) and Equipe Mixte Inserm (EMI 106), Faculté de Médecine Dijon;</affiliation></author><author xml:id="author-4"><persName><forename type="first">C.</forename><surname>Mariette</surname></persName><affiliation>Centre Hospitalier Universitaire Claude Huriez, Lille;</affiliation><affiliation>Fédération Francophone de Cancérologie Digestive (FFCD) and Equipe Mixte Inserm (EMI 106), Faculté de Médecine Dijon;</affiliation></author><author xml:id="author-5"><persName><forename type="first">T.</forename><surname>Conroy</surname></persName><affiliation>Centre Alexis Vautrin, Nancy;</affiliation><affiliation>Fédération Francophone de Cancérologie Digestive (FFCD) and Equipe Mixte Inserm (EMI 106), Faculté de Médecine Dijon;</affiliation></author><author xml:id="author-6"><persName><forename type="first">D.</forename><surname>Pezet</surname></persName><affiliation>Centre Hospitalier Universitaire Hôtel Dieu, Clermond Ferrand;</affiliation><affiliation>Fédération Francophone de Cancérologie Digestive (FFCD) and Equipe Mixte Inserm (EMI 106), Faculté de Médecine Dijon;</affiliation></author><author xml:id="author-7"><persName><forename type="first">B.</forename><surname>Roullet</surname></persName><affiliation>Centre Hospitalier Universitaire Dupuytren, Limoges;</affiliation><affiliation>Fédération Francophone de Cancérologie Digestive (FFCD) and Equipe Mixte Inserm (EMI 106), Faculté de Médecine Dijon;</affiliation></author><author xml:id="author-8"><persName><forename type="first">J.-F.</forename><surname>Seitz</surname></persName><affiliation>Institut Paoli-Calmettes, Marseille;</affiliation><affiliation>Fédération Francophone de Cancérologie Digestive (FFCD) and Equipe Mixte Inserm (EMI 106), Faculté de Médecine Dijon;</affiliation></author><author xml:id="author-9"><persName><forename type="first">B.</forename><surname>Paillot</surname></persName><affiliation>Centre Hospitalier Universitaire du Rouen, Rouen, France</affiliation><affiliation>Fédération Francophone de Cancérologie Digestive (FFCD) and Equipe Mixte Inserm (EMI 106), Faculté de Médecine Dijon;</affiliation></author><author xml:id="author-10"><persName><forename type="first">P.</forename><surname>Arveux</surname></persName><affiliation>Centre Georges Francois Leclerc, DIM, Dijon;</affiliation><affiliation>Fédération Francophone de Cancérologie Digestive (FFCD) and Equipe Mixte Inserm (EMI 106), Faculté de Médecine Dijon;</affiliation></author><author xml:id="author-11"><persName><forename type="first">C.</forename><surname>Milan</surname></persName><affiliation>Fédération Francophone de Cancérologie Digestive (FFCD) and Equipe Mixte Inserm (EMI 106), Faculté de Médecine Dijon;</affiliation><affiliation>Fédération Francophone de Cancérologie Digestive (FFCD) and Equipe Mixte Inserm (EMI 106), Faculté de Médecine Dijon;</affiliation></author><author xml:id="author-12"><persName><forename type="first">L.</forename><surname>Bedenne</surname></persName><affiliation>Fédération Francophone de Cancérologie Digestive (FFCD) and Equipe Mixte Inserm (EMI 106), Faculté de Médecine Dijon;</affiliation><affiliation>Fédération Francophone de Cancérologie Digestive (FFCD) and Equipe Mixte Inserm (EMI 106), Faculté de Médecine Dijon;</affiliation></author></analytic><monogr><title level="j">Annals of Oncology</title><title level="j" type="abbrev">Ann Oncol</title><idno type="pISSN">0923-7534</idno><idno type="eISSN">1569-8041</idno><imprint><publisher>Oxford University Press</publisher><date type="published" when="2006-05"></date><biblScope unit="volume">17</biblScope><biblScope unit="issue">5</biblScope><biblScope unit="page" from="827">827</biblScope><biblScope unit="page" to="834">834</biblScope></imprint></monogr><idno type="istex">FDE39442EAAA5F05C7C30FA79230D923131D83A9</idno><idno type="DOI">10.1093/annonc/mdl033</idno><idno type="local">mdl033</idno></biblStruct></sourceDesc></fileDesc><profileDesc><creation><date>2006-03-08</date></creation><langUsage><language ident="en">en</language></langUsage><abstract xml:lang="en"><p>Background: The aim of the study was to compare the longitudinal quality of life (QoL) between chemoradiation with or without surgery in patients with locally advanced squamous resectable esophageal cancer included in a randomized multicenter phase III trial (FFCD 9102). Materials and methods: All patients with locally advanced resectable (T3–4 N0–1 M0) epidermoid or glandular esophageal cancer (n = 451) received induction chemoradiation. Responders (n = 259) were randomized between surgery (arm A) and continuation of chemoradiation (arm B). The Spitzer QoL Index was scored (0–10) at inclusion and at each follow-up, every 3 months during 2 years. QoL at baseline and longitudinal changes were respectively compared with univariate ANOVA and mixed-model analysis of variance for repeated measurements. The time interval between the follow-up was assessed and the same analyses were performed among survivors with 2 years of follow-up. Results: The squamous histology was predominant in both arms. The mean QoL score decreased between baseline and the first follow-up and between the first and the second follow-ups. QoL scores at the first follow-up were comparatively worse in arm A than in arm B (7.52 versus 8.45, P < 0.01), whereas the longitudinal QoL study showed no difference between treatments (adjusted P = 0.26). Furthermore, the longitudinal QoL was not different (adjusted P = 0.23) among survivors with 2 years of follow-up. Conclusions: Among patients responding to induction chemoradiation, surgery and continuation of chemoradiation had the same impact on QoL in patients with locally advanced, resectable esophageal cancer although a significantly greater decrease in the Spitzer Index was observed in the postoperative period.</p></abstract><textClass xml:lang="en"><keywords scheme="keyword"><list><head>KWD</head><item><term>quality of life</term></item><item><term>esophageal cancer</term></item><item><term>clinical trials</term></item><item><term>longitudinal</term></item><item><term>surgery</term></item><item><term>radio-chemotherapy</term></item></list></keywords></textClass></profileDesc><revisionDesc><change when="2006-03-08">Created</change><change when="2006-05">Published</change><change xml:id="refBibs-istex" who="#ISTEX-API" when="2016-10-14">References added</change></revisionDesc></teiHeader></istex:fulltextTEI><json:item><original>false</original><mimetype>text/plain</mimetype><extension>txt</extension><uri>https://api.istex.fr/document/FDE39442EAAA5F05C7C30FA79230D923131D83A9/fulltext/txt</uri></json:item></fulltext><metadata><istex:metadataXml wicri:clean="corpus oup" wicri:toSee="no header"><istex:xmlDeclaration>version="1.0" encoding="US-ASCII"</istex:xmlDeclaration><istex:docType PUBLIC="-//NLM//DTD Journal Publishing DTD v2.3 20070202//EN" URI="journalpublishing.dtd" name="istex:docType"></istex:docType><istex:document><article xml:lang="en" article-type="research-article"><front><journal-meta><journal-id journal-id-type="hwp">annonc</journal-id><journal-id journal-id-type="nlm-ta">Ann Oncol</journal-id><journal-id journal-id-type="publisher-id">annonc</journal-id><journal-title>Annals of Oncology</journal-title><abbrev-journal-title abbrev-type="publisher">Ann Oncol</abbrev-journal-title><issn pub-type="ppub">0923-7534</issn><issn pub-type="epub">1569-8041</issn><publisher><publisher-name>Oxford University Press</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="other">mdl033</article-id><article-id pub-id-type="doi">10.1093/annonc/mdl033</article-id><article-categories><subj-group subj-group-type="heading"><subject>Original article</subject><subj-group><subject>gastrointestinal tumors</subject></subj-group></subj-group></article-categories><title-group><article-title>A comparative longitudinal quality of life study using the Spitzer quality of life index in a randomized multicenter phase III trial (FFCD 9102): chemoradiation followed by surgery compared with chemoradiation alone in locally advanced squamous resectable thoracic esophageal cancer</article-title></title-group><contrib-group><contrib contrib-type="author"><name><surname>Bonnetain</surname><given-names>F.</given-names></name><xref rid="AFF1"><sup>1</sup></xref><xref rid="AFF2"><sup>2</sup></xref><xref rid="COR1"><sup>*</sup></xref></contrib><contrib contrib-type="author"><name><surname>Bouché</surname><given-names>O.</given-names></name><xref rid="AFF3"><sup>3</sup></xref></contrib><contrib contrib-type="author"><name><surname>Michel</surname><given-names>P.</given-names></name><xref rid="AFF4"><sup>4</sup></xref></contrib><contrib contrib-type="author"><name><surname>Mariette</surname><given-names>C.</given-names></name><xref rid="AFF5"><sup>5</sup></xref></contrib><contrib contrib-type="author"><name><surname>Conroy</surname><given-names>T.</given-names></name><xref rid="AFF6"><sup>6</sup></xref></contrib><contrib contrib-type="author"><name><surname>Pezet</surname><given-names>D.</given-names></name><xref rid="AFF7"><sup>7</sup></xref></contrib><contrib contrib-type="author"><name><surname>Roullet</surname><given-names>B.</given-names></name><xref rid="AFF8"><sup>8</sup></xref></contrib><contrib contrib-type="author"><name><surname>Seitz</surname><given-names>J.-F.</given-names></name><xref rid="AFF9"><sup>9</sup></xref></contrib><contrib contrib-type="author"><name><surname>Paillot</surname><given-names>B.</given-names></name><xref rid="AFF10"><sup>10</sup></xref></contrib><contrib contrib-type="author"><name><surname>Arveux</surname><given-names>P.</given-names></name><xref rid="AFF2"><sup>2</sup></xref></contrib><contrib contrib-type="author"><name><surname>Milan</surname><given-names>C.</given-names></name><xref rid="AFF1"><sup>1</sup></xref></contrib><contrib contrib-type="author"><name><surname>Bedenne</surname><given-names>L.</given-names></name><xref rid="AFF1"><sup>1</sup></xref><xref rid="AFF2"><sup>2</sup></xref></contrib><aff><target target-type="aff" id="AFF1"></target><label>1</label>Fédération Francophone de Cancérologie Digestive (FFCD) and Equipe Mixte Inserm (EMI 106), Faculté de Médecine Dijon; <target target-type="aff" id="AFF2"></target><label>2</label>Centre Georges Francois Leclerc, DIM, Dijon; <target target-type="aff" id="AFF3"></target><label>3</label>Centre Hospitalier Universitaire Robert Debré, Reims; <target target-type="aff" id="AFF4"></target><label>4</label>Centre Hospitalier Universitaire Charles Nicolle, Rouen; <target target-type="aff" id="AFF5"></target><label>5</label>Centre Hospitalier Universitaire Claude Huriez, Lille; <target target-type="aff" id="AFF6"></target><label>6</label>Centre Alexis Vautrin, Nancy; <target target-type="aff" id="AFF7"></target><label>7</label>Centre Hospitalier Universitaire Hôtel Dieu, Clermond Ferrand; <target target-type="aff" id="AFF8"></target><label>8</label>Centre Hospitalier Universitaire Dupuytren, Limoges; <target target-type="aff" id="AFF9"></target><label>9</label>Institut Paoli-Calmettes, Marseille; <target target-type="aff" id="AFF10"></target><label>10</label>Centre Hospitalier Universitaire du Rouen, Rouen, France</aff></contrib-group><author-notes><corresp id="COR1"><label>*</label><italic>Correspondence to:</italic> Dr F. Bonnetain, Féderation Francophone de Cancérologie Digestive, Faculty of Medicine, 7 Boulevard Jeanne d'Arc, 21079 Dijon Cedex, France. Tel: +33-3-80-39-33-40; Fax: +33-3-80-66-82-51; E-mail: <ext-link xlink:href="FBonnetain@dijon.fnclcc.fr" ext-link-type="email">FBonnetain@dijon.fnclcc.fr</ext-link></corresp></author-notes><pub-date pub-type="epub"><day>8</day><month>3</month><year>2006</year></pub-date><pub-date pub-type="ppub"><month>May</month><year>2006</year></pub-date><volume>17</volume><issue>5</issue><fpage>827</fpage><lpage>834</lpage><history><date date-type="accepted"><day>30</day><month>1</month><year>2006</year></date><date date-type="received"><day>7</day><month>10</month><year>2005</year></date><date date-type="rev-recd"><day>25</day><month>1</month><year>2006</year></date></history><permissions><copyright-statement>© 2006 European Society for Medical Oncology</copyright-statement><copyright-year>2006</copyright-year></permissions><abstract xml:lang="en"><p><bold>Background:</bold> The aim of the study was to compare the longitudinal quality of life (QoL) between chemoradiation with or without surgery in patients with locally advanced squamous resectable esophageal cancer included in a randomized multicenter phase III trial (FFCD 9102).</p><p><bold>Materials and methods:</bold> All patients with locally advanced resectable (T3–4 N0–1 M0) epidermoid or glandular esophageal cancer (<italic>n</italic> = 451) received induction chemoradiation. Responders (<italic>n</italic> = 259) were randomized between surgery (arm A) and continuation of chemoradiation (arm B). The Spitzer QoL Index was scored (0–10) at inclusion and at each follow-up, every 3 months during 2 years. QoL at baseline and longitudinal changes were respectively compared with univariate ANOVA and mixed-model analysis of variance for repeated measurements. The time interval between the follow-up was assessed and the same analyses were performed among survivors with 2 years of follow-up.</p><p><bold>Results:</bold> The squamous histology was predominant in both arms. The mean QoL score decreased between baseline and the first follow-up and between the first and the second follow-ups. QoL scores at the first follow-up were comparatively worse in arm A than in arm B (7.52 versus 8.45, <italic>P</italic> < 0.01), whereas the longitudinal QoL study showed no difference between treatments (adjusted <italic>P</italic> = 0.26). Furthermore, the longitudinal QoL was not different (adjusted <italic>P</italic> = 0.23) among survivors with 2 years of follow-up.</p><p><bold>Conclusions:</bold> Among patients responding to induction chemoradiation, surgery and continuation of chemoradiation had the same impact on QoL in patients with locally advanced, resectable esophageal cancer although a significantly greater decrease in the Spitzer Index was observed in the postoperative period.</p></abstract><kwd-group kwd-group-type="KWD" xml:lang="en"><kwd>quality of life</kwd><kwd>esophageal cancer</kwd><kwd>clinical trials</kwd><kwd>longitudinal</kwd><kwd>surgery</kwd><kwd>radio-chemotherapy</kwd></kwd-group><custom-meta-wrap><custom-meta><meta-name>hwp-legacy-fpage</meta-name><meta-value>827</meta-value></custom-meta><custom-meta><meta-name>cover-date</meta-name><meta-value>May 2006</meta-value></custom-meta><custom-meta><meta-name>hwp-legacy-dochead</meta-name><meta-value>original article</meta-value></custom-meta></custom-meta-wrap></article-meta></front></article></istex:document></istex:metadataXml><mods version="3.6"><titleInfo lang="en"><title>A comparative longitudinal quality of life study using the Spitzer quality of life index in a randomized multicenter phase III trial (FFCD 9102): chemoradiation followed by surgery compared with chemoradiation alone in locally advanced squamous resectable thoracic esophageal cancer</title></titleInfo><titleInfo type="alternative" lang="en" contentType="CDATA"><title>A comparative longitudinal quality of life study using the Spitzer quality of life index in a randomized multicenter phase III trial (FFCD 9102): chemoradiation followed by surgery compared with chemoradiation alone in locally advanced squamous resectable thoracic esophageal cancer</title></titleInfo><name type="personal"><namePart type="given">F.</namePart><namePart type="family">Bonnetain</namePart><affiliation>Fédération Francophone de Cancérologie Digestive (FFCD) and Equipe Mixte Inserm (EMI 106), Faculté de Médecine Dijon;</affiliation><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">O.</namePart><namePart type="family">Bouché</namePart><affiliation>Centre Hospitalier Universitaire Robert Debré, Reims;</affiliation><affiliation>Fédération Francophone de Cancérologie Digestive (FFCD) and Equipe Mixte Inserm (EMI 106), Faculté de Médecine Dijon;</affiliation><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">P.</namePart><namePart type="family">Michel</namePart><affiliation>Centre Hospitalier Universitaire Charles Nicolle, Rouen;</affiliation><affiliation>Fédération Francophone de Cancérologie Digestive (FFCD) and Equipe Mixte Inserm (EMI 106), Faculté de Médecine Dijon;</affiliation><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">C.</namePart><namePart type="family">Mariette</namePart><affiliation>Centre Hospitalier Universitaire Claude Huriez, Lille;</affiliation><affiliation>Fédération Francophone de Cancérologie Digestive (FFCD) and Equipe Mixte Inserm (EMI 106), Faculté de Médecine Dijon;</affiliation><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">T.</namePart><namePart type="family">Conroy</namePart><affiliation>Centre Alexis Vautrin, Nancy;</affiliation><affiliation>Fédération Francophone de Cancérologie Digestive (FFCD) and Equipe Mixte Inserm (EMI 106), Faculté de Médecine Dijon;</affiliation><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">D.</namePart><namePart type="family">Pezet</namePart><affiliation>Centre Hospitalier Universitaire Hôtel Dieu, Clermond Ferrand;</affiliation><affiliation>Fédération Francophone de Cancérologie Digestive (FFCD) and Equipe Mixte Inserm (EMI 106), Faculté de Médecine Dijon;</affiliation><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">B.</namePart><namePart type="family">Roullet</namePart><affiliation>Centre Hospitalier Universitaire Dupuytren, Limoges;</affiliation><affiliation>Fédération Francophone de Cancérologie Digestive (FFCD) and Equipe Mixte Inserm (EMI 106), Faculté de Médecine Dijon;</affiliation><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">J.-F.</namePart><namePart type="family">Seitz</namePart><affiliation>Institut Paoli-Calmettes, Marseille;</affiliation><affiliation>Fédération Francophone de Cancérologie Digestive (FFCD) and Equipe Mixte Inserm (EMI 106), Faculté de Médecine Dijon;</affiliation><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">B.</namePart><namePart type="family">Paillot</namePart><affiliation>Centre Hospitalier Universitaire du Rouen, Rouen, France</affiliation><affiliation>Fédération Francophone de Cancérologie Digestive (FFCD) and Equipe Mixte Inserm (EMI 106), Faculté de Médecine Dijon;</affiliation><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">P.</namePart><namePart type="family">Arveux</namePart><affiliation>Centre Georges Francois Leclerc, DIM, Dijon;</affiliation><affiliation>Fédération Francophone de Cancérologie Digestive (FFCD) and Equipe Mixte Inserm (EMI 106), Faculté de Médecine Dijon;</affiliation><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">C.</namePart><namePart type="family">Milan</namePart><affiliation>Fédération Francophone de Cancérologie Digestive (FFCD) and Equipe Mixte Inserm (EMI 106), Faculté de Médecine Dijon;</affiliation><affiliation>Fédération Francophone de Cancérologie Digestive (FFCD) and Equipe Mixte Inserm (EMI 106), Faculté de Médecine Dijon;</affiliation><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">L.</namePart><namePart type="family">Bedenne</namePart><affiliation>Fédération Francophone de Cancérologie Digestive (FFCD) and Equipe Mixte Inserm (EMI 106), Faculté de Médecine Dijon;</affiliation><affiliation>Fédération Francophone de Cancérologie Digestive (FFCD) and Equipe Mixte Inserm (EMI 106), Faculté de Médecine Dijon;</affiliation><role><roleTerm type="text">author</roleTerm></role></name><typeOfResource>text</typeOfResource><genre type="research-article" displayLabel="research-article"></genre><originInfo><publisher>Oxford University Press</publisher><dateIssued encoding="w3cdtf">2006-05</dateIssued><dateCreated encoding="w3cdtf">2006-03-08</dateCreated><copyrightDate encoding="w3cdtf">2006</copyrightDate></originInfo><language><languageTerm type="code" authority="iso639-2b">eng</languageTerm><languageTerm type="code" authority="rfc3066">en</languageTerm></language><physicalDescription><internetMediaType>text/html</internetMediaType></physicalDescription><abstract lang="en">Background: The aim of the study was to compare the longitudinal quality of life (QoL) between chemoradiation with or without surgery in patients with locally advanced squamous resectable esophageal cancer included in a randomized multicenter phase III trial (FFCD 9102). Materials and methods: All patients with locally advanced resectable (T3–4 N0–1 M0) epidermoid or glandular esophageal cancer (n = 451) received induction chemoradiation. Responders (n = 259) were randomized between surgery (arm A) and continuation of chemoradiation (arm B). The Spitzer QoL Index was scored (0–10) at inclusion and at each follow-up, every 3 months during 2 years. QoL at baseline and longitudinal changes were respectively compared with univariate ANOVA and mixed-model analysis of variance for repeated measurements. The time interval between the follow-up was assessed and the same analyses were performed among survivors with 2 years of follow-up. Results: The squamous histology was predominant in both arms. The mean QoL score decreased between baseline and the first follow-up and between the first and the second follow-ups. QoL scores at the first follow-up were comparatively worse in arm A than in arm B (7.52 versus 8.45, P < 0.01), whereas the longitudinal QoL study showed no difference between treatments (adjusted P = 0.26). Furthermore, the longitudinal QoL was not different (adjusted P = 0.23) among survivors with 2 years of follow-up. Conclusions: Among patients responding to induction chemoradiation, surgery and continuation of chemoradiation had the same impact on QoL in patients with locally advanced, resectable esophageal cancer although a significantly greater decrease in the Spitzer Index was observed in the postoperative period.</abstract><note type="author-notes">*Correspondence to: Dr F. Bonnetain, Féderation Francophone de Cancérologie Digestive, Faculty of Medicine, 7 Boulevard Jeanne d'Arc, 21079 Dijon Cedex, France. Tel: +33-3-80-39-33-40; Fax: +33-3-80-66-82-51; E-mail: FBonnetain@dijon.fnclcc.fr</note><subject lang="en"><genre>KWD</genre><topic>quality of life</topic><topic>esophageal cancer</topic><topic>clinical trials</topic><topic>longitudinal</topic><topic>surgery</topic><topic>radio-chemotherapy</topic></subject><relatedItem type="host"><titleInfo><title>Annals of Oncology</title></titleInfo><titleInfo type="abbreviated"><title>Ann Oncol</title></titleInfo><genre type="journal">journal</genre><identifier type="ISSN">0923-7534</identifier><identifier type="eISSN">1569-8041</identifier><identifier type="PublisherID">annonc</identifier><identifier type="PublisherID-hwp">annonc</identifier><identifier type="PublisherID-nlm-ta">Ann Oncol</identifier><part><date>2006</date><detail type="volume"><caption>vol.</caption><number>17</number></detail><detail type="issue"><caption>no.</caption><number>5</number></detail><extent unit="pages"><start>827</start><end>834</end></extent></part></relatedItem><identifier type="istex">FDE39442EAAA5F05C7C30FA79230D923131D83A9</identifier><identifier type="DOI">10.1093/annonc/mdl033</identifier><identifier type="local">mdl033</identifier><accessCondition type="use and reproduction" contentType="copyright">© 2006 European Society for Medical Oncology</accessCondition><recordInfo><recordContentSource>OUP</recordContentSource></recordInfo></mods></metadata><covers><json:item><original>true</original><mimetype>image/gif</mimetype><extension>gif</extension><uri>https://api.istex.fr/document/FDE39442EAAA5F05C7C30FA79230D923131D83A9/covers/gif</uri></json:item><json:item><original>true</original><mimetype>image/tiff</mimetype><extension>tiff</extension><uri>https://api.istex.fr/document/FDE39442EAAA5F05C7C30FA79230D923131D83A9/covers/tiff</uri></json:item></covers><annexes><json:item><original>true</original><mimetype>image/jpeg</mimetype><extension>jpeg</extension><uri>https://api.istex.fr/document/FDE39442EAAA5F05C7C30FA79230D923131D83A9/annexes/jpeg</uri></json:item></annexes><enrichments><istex:catWosTEI uri="https://api.istex.fr/document/FDE39442EAAA5F05C7C30FA79230D923131D83A9/enrichments/catWos"><teiHeader><profileDesc><textClass><classCode scheme="WOS">ONCOLOGY</classCode></textClass></profileDesc></teiHeader></istex:catWosTEI><json:item><type>refBibs</type><uri>https://api.istex.fr/document/FDE39442EAAA5F05C7C30FA79230D923131D83A9/enrichments/refBibs</uri></json:item></enrichments><serie></serie></istex></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Wicri/France/explor/LeHavreV1/Data/Istex/Corpus
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 001761 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Istex/Corpus/biblio.hfd -nk 001761 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Wicri/France
|area= LeHavreV1
|flux= Istex
|étape= Corpus
|type= RBID
|clé= ISTEX:FDE39442EAAA5F05C7C30FA79230D923131D83A9
|texte= A comparative longitudinal quality of life study using the Spitzer quality of life index in a randomized multicenter phase III trial (FFCD 9102): chemoradiation followed by surgery compared with chemoradiation alone in locally advanced squamous resectable thoracic esophageal cancer
}}
| This area was generated with Dilib version V0.6.25. |  |